| 321.02 0.39 (0.12%) | 06-05 13:47 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 379.77 | 1-year : | 385.05 |
| Resists | First : | 325.14 | Second : | 329.67 |
| Pivot price | 322.95  |
|||
| Supports | First : | 317.82 | Second : | 264.43 |
| MAs | MA(5) : | 319.82  |
MA(20) : | 322.82 |
| MA(100) : | 334.45 |
MA(250) : | 293.26 |
|
| MACD | MACD : | -2.1 |
Signal : | -1.9 |
| %K %D | K(14,3) : | 22.3 |
D(3) : | 15.7 |
| RSI | RSI(14): 43.1 |
|||
| 52-week | High : | 362.41 | Low : | 221.25 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PEN ] has closed above bottom band by 40.2%. Bollinger Bands are 25.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 323.52 - 324.83 | 324.83 - 326.07 |
| Low: | 316.57 - 318.04 | 318.04 - 319.43 |
| Close: | 318.31 - 320.58 | 320.58 - 322.75 |
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
Fri, 05 Jun 2026
Here’s What Supports Penumbra’s (PEN) Revenue Growth and Margin Expansion - Yahoo Finance
Thu, 04 Jun 2026
Grewal Harpreet, Penumbra director, sells $32,822 in stock - Investing.com
Wed, 03 Jun 2026
JP Morgan Upgrades Penumbra (PEN) - MSN
Mon, 01 Jun 2026
Penumbra, Inc. (PEN) Stock Analysis: A Look At Growth Potential With A 14% Upside - DirectorsTalk Interviews
Sun, 31 May 2026
Decagon Asset Management LLP's Penumbra Inc(PEN) Holding History - GuruFocus
Mon, 25 May 2026
Penumbra, Inc. (PEN) Stock Analysis: A Healthcare Giant With A 10.55% Upside Potential - DirectorsTalk Interviews
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 39 (M) |
| Shares Float | 38 (M) |
| Held by Insiders | 2.9 (%) |
| Held by Institutions | 87.9 (%) |
| Shares Short | 1,920 (K) |
| Shares Short P.Month | 2,010 (K) |
| EPS | 4.32 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 36.38 |
| Profit Margin | 11.7 % |
| Operating Margin | 10.1 % |
| Return on Assets (ttm) | 6.6 % |
| Return on Equity (ttm) | 12.7 % |
| Qtrly Rev. Growth | 15.6 % |
| Gross Profit (p.s.) | 24.91 |
| Sales Per Share | 36.86 |
| EBITDA (p.s.) | 5.18 |
| Qtrly Earnings Growth | -18 % |
| Operating Cash Flow | 277 (M) |
| Levered Free Cash Flow | 142 (M) |
| PE Ratio | 74.23 |
| PEG Ratio | 0.7 |
| Price to Book value | 8.83 |
| Price to Sales | 8.71 |
| Price to Cash Flow | 45.69 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|